Related Experiment Videos
Huntington's disease: recent advances in diagnosis and management
1Department of Clinical Neurosciences, Faculty of Medicine, University of Calgary, Alberta, Canada.
Insights
Huntington's Disease (HD) is an inherited neurodegenerative disorder affecting the central nervous system. Genetic testing is now available for diagnosis and presymptomatic identification, paving the way for potential future treatments.
Area of Science:
- Genetics
- Neuroscience
- Molecular Biology
Background:
- Huntington's Disease (HD) is an autosomal dominant inherited neurodegenerative disorder.
- Characterized by choreoathetosis and neuropsychiatric symptoms, typically with onset in adulthood.
- Pathological hallmarks include striatal medium spiny neuron loss and altered neurotransmitter levels.
Purpose of the Study:
- To summarize the current understanding of Huntington's Disease (HD) pathogenesis and diagnosis.
- To highlight recent advances in genetic discovery and diagnostic testing.
- To discuss the implications for future therapeutic strategies.
Main Methods:
- Review of existing literature on Huntington's Disease.
- Characterization of the HD gene (IT15) and its CAG trinucleotide repeat expansion.
- Discussion of diagnostic methodologies including genetic testing.
Main Results:
- The gene responsible for HD has been identified as IT15, featuring an unstable CAG trinucleotide repeat.
- Genetic testing facilitates accurate diagnosis, including presymptomatic identification.
- Current management focuses on symptomatic relief due to unknown pathophysiology.
Conclusions:
- The discovery of the HD gene offers a direct diagnostic tool.
- Understanding the genetic basis provides a foundation for developing targeted therapies.
- Future research holds promise for effective treatments for Huntington's Disease.
Abstract:
Huntington's Disease (HD) is a progressive degenerative disorder of the central nervous system inherited as an autosomal dominant trait. Clinically, the disorder is characterized by choreoathetosis (with age of onset typically in the late thirties or early forties) and neuropsychiatric disturbance. The striatum is particularly vulnerable to the degenerative disease process, with selective loss of medium spiny neurons and decreased levels of associated neurotransmitters, including substance P. GABA, met-enkephalin and dynorphin. Although the underlying pathophysiology is unknown, recent theories concerning pathogenesis have involved mitochondrial abnormalities and excitotoxin-mediated damage. The gene for HD has recently been discovered and characterized as an unstable CAG trinucleotide repeat sequence on the short arm of chromosome 4 (now known as IT15). The direct test now available for the HD gene has facilitated disease diagnosis, particularly for those with unclear family history or chorea of uncertain origin; presymptomatic testing is also available. Management of affected individuals is unsatisfactory as only symptomatic control is available. However, as the effect of the genetic abnormality may soon be known, specific treatment of the disorder may become available in the near future.